Trials / Completed
CompletedNCT00259116
A Pilot Study of Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure
A Pilot Safety and Dose-Finding Trial of Intravenous Recombinant Human Relaxin (rhRlx) in Compensated Congestive Heart Failure
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 18 (planned)
- Sponsor
- Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies · Industry
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This trial is a single center, open-label, dose-finding study of recombinant human relaxin (rhRlx) given intravenously (IV) to patients with stable, compensated CHF.
Detailed description
Serial cohorts of patients with stable CHF will be enrolled upon meeting eligibility criteria. Dose escalation will be guided by hemodynamic response, safety and tolerability. The effects of rhRlx on hemodynamics will be assessed.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Relaxin |
Timeline
- Start date
- 2005-11-01
- First posted
- 2005-11-29
- Last updated
- 2009-04-15
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00259116. Inclusion in this directory is not an endorsement.